Pathogenetic Justification for the Use of Immunomodulatory Drugs in the Complex Treatment of Atypical Forms of Endometriosis

Endometriosis is a complex condition characterized by the growth of endometrial tissue outside the uterine cavity. Its clinical forms, particularly ovarian endometriosis or peritoneal endometriosis, require a differentiated approach to treatment due to the complexity of their pathogenesis. The aim of the study is to justify the use of immunomodulatory drugs in the comprehensive treatment of atypical forms of endometriosis by analyzing pathogenetic mechanisms, as well as to evaluate their efficacy and develop practical recommendations. The study employed theoretical (analysis, synthesis, abstraction, induction, deduction) and empirical methods (observation, experiment, description). The pathogenetic mechanism of endometriosis development encompasses several key aspects: cytokine imbalance (increased levels of pro-inflammatory cytokines such as interleukin (IL)-1, IL-6, tumor necrosis factor-α, and a decrease in the anti-inflammatory IL-10), hormonal dysfunction (elevated estrogen levels and decreased progesterone), genetic predisposition (mutations in genes regulating the immune response), chronic local immune activation (accumulation of macrophages and T-lymphocytes in endometriosis lesions), and oxidative stress (increased levels of free radicals in tissues). This study examines the efficacy of immunomodulatory drugs in correcting immune disorders in atypical forms of endometriosis. In particular, various groups of agents are analyzed: cytokine immunomodulators (interferons), antioxidant-immunomodulatory compounds (alpha-lipoic acid), vitamin D (cholecalciferol), phytonutrients with immunomodulatory properties (indole-3-carbinol, epigallocatechin-3-gallate), as well as combination therapy (hormonal drugs in combination with immunomodulators). Clinical results demonstrated a reduction in the progression of endometriosis lesions, improved oocyte quality, stabilization of the disease course, and a decrease in the recurrence rate. Based on the obtained data, practical recommendations were developed for the integration of immunomodulatory drugs into the comprehensive treatment of atypical forms of endometriosis. The recommendations include individualized drug selection based on the immunological profile, combined sequential therapy, regular monitoring of efficacy, and synergy with primary treatment methods. The practical significance of the study lies in the fact that the introduction of immunomodulatory drugs into clinical practice can significantly improve patients’ quality of life, reduce the frequency of relapses, and increase the effectiveness of treatment.